Latest profit margin for Exelixis: 33.14% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Exelixis (EXEL) currently reports a profit margin of 33.14% as of March 2026. That compares with 28.76% in the prior-year period — up 15.2% year over year. That is above the Healthcare sector average of 15.29%. Use the charts on this page to explore Exelixis's profit margin history and peer comparisons.
Exelixis's profit margin increased from 28.76% to 33.14% — a 15.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Exelixis's profit margin of 33.14% is higher than the Healthcare sector average of 15.29%. That is roughly 116.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Exelixis's current 33.14% should be judged against Healthcare norms (sector average: 15.29%) and against EXEL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of 33.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Exelixis, and consider following EXEL for alerts when major investors trade the stock.